The Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cell Secretome in Osteoarthritis: A Comprehensive Study. The Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cell Secretome in Osteoarthritis: A Comprehensive Study

Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage degradation and inflammation. This study investigates the therapeutic potential of secretome derived from adipose tissue mesenchymal stem cells (ASCs) in mitigating inflammation and promoting cartilage repair in an in vitro model of OA. Our in vitro model comprised chondrocytes inflamed with TNF. To assess the therapeutic potential of secretome, inflamed chondrocytes were treated with it and concentrations of pro-inflammatory cytokines, metalloproteinases (MMPs) and extracellular matrix markers were measured. In addition, secretome-treated chondrocytes were subject to a microarray analysis to determine which genes were upregulated and which were downregulated. Treating TNF-inflamed chondrocytes with secretome in vitro inhibits the NF-κB pathway, thereby mediating anti-inflammatory and anti-catabolic effects. Additional protective effects of secretome on cartilage are revealed in the inhibition of hypertrophy markers such as RUNX2 and COL10A1, increased production of COL2A1 and ACAN and upregulation of SOX9. These findings suggest that ASC-derived secretome can effectively reduce inflammation, promote cartilage repair, and maintain chondrocyte phenotype. This study highlights the potential of ASC-derived secretome as a novel, non-cell-based therapeutic approach for OA, offering a promising alternative to current treatments by targeting inflammation and cartilage repair mechanisms. Overall design: Four different conditons were analysed: 1. Condrocytes 2. AT-MSCs 3. Inflamed chondrocytes 4. Inflamed chondrocytes treated with CM. All experiments were completed in triplicate.

骨关节炎（Osteoarthritis, OA）是一类以软骨退变与炎症为特征的退行性关节疾病。本研究旨在探究脂肪组织间充质干细胞（Adipose Tissue Mesenchymal Stem Cells, ASCs）分泌组在骨关节炎体外模型中缓解炎症、促进软骨修复的治疗潜力。本研究所用的体外模型为经肿瘤坏死因子（Tumor Necrosis Factor, TNF）诱导炎症的软骨细胞。为评估该分泌组的治疗潜力，研究人员将其作用于炎症状态的软骨细胞，并检测了促炎细胞因子、基质金属蛋白酶（Matrix Metalloproteinases, MMPs）及细胞外基质标志物的表达水平。此外，研究人员还对经分泌组处理的软骨细胞开展了基因芯片分析，以确定上调及下调的差异基因。

体外实验结果显示，用分泌组处理经TNF诱导炎症的软骨细胞可抑制核因子-κB（Nuclear Factor-kappa B, NF-κB）通路，进而发挥抗炎与抗分解代谢作用。此外，分泌组还可通过抑制RUNX2、COL10A1等肥大标志物的表达，上调COL2A1与ACAN的生成并增强SOX9的表达，从而对软骨发挥额外的保护作用。上述研究结果表明，ASCs来源的分泌组可有效减轻炎症、促进软骨修复并维持软骨细胞表型。本研究证实了ASCs分泌组作为一种新型非细胞治疗策略治疗OA的潜力，其通过靶向炎症与软骨修复机制，为现有临床治疗方案提供了极具前景的替代选择。

实验设计：本研究共分析4种实验条件：1. 软骨细胞；2. 脂肪组织间充质干细胞；3. 炎症状态软骨细胞；4. 经条件培养基（Conditioned Medium, CM）处理的炎症状态软骨细胞。所有实验均设置3次生物学重复。